Cytokinetics Inc stock is traded at $56.13, with a volume of 1,013,535. It is down -0.05% in the last 24 hours and down -8.91% over the past month. Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
Previous Close:
$56.16
Open:
$56.55
24h Volume:
1,013,535
Relative Volume:
0.38
Market Cap:
$7.82B
Revenue:
$105.82M
Net Income/Loss:
-$829.61M
P/E Ratio:
-
EPS:
-$6.84
Net Cash Flow:
-$548.92M
1W Performance:
+4.54%
1M Performance:
-8.91%
6M Performance:
-27.31%
1Y Performance:
-14.33%
1-Day Range:
$55.15$56.66
1-Week Range:
$53.58$59.08
52-Week Range:
$53.55$88.31
Cytokinetics Inc Stock (CYTK) Company Profile
Name
Cytokinetics IncSector
HealthcareIndustry
BiotechnologyPhone
(650) 624-3000Address
350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS